Stock Analiz

bioAffinity Technologies, Inc. BIAF

Biotechnology: Commercial Physical & Biological Resarch · IPO 2022 · data as of November 13, 2026

$2.20Market cap $4M
Open the interactive analysis →

bioAffinity Technologies, Inc. (BIAF) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$15M, a net margin of -278.9%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -118%.

About bioAffinity Technologies

bioAffinity Technologies is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2022. Revenue went from $7M in 2022 to $6M in 2025, a decline of about 3.7% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 1048% over three years (dilution for shareholders). It spends 22% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.7
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-325.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-34.2%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-139.3%
ROIC (5-yr avg.)-118.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$6M$6M$9M$8M$7M—
Net income-$15M-$15M-$9M-$8M-$8M-$6M
Free cash flow-$13M-$9M-$7M-$6M-$4M—
EPS (diluted)$-8.95$-8.66$-22.50$-27.30$-54.30$-70.80
Net margin-278.9%-242.0%-96.6%-100.5%-118.2%—
ROIC—-107.5%-216.7%-120.4%-28.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does bioAffinity Technologies pay a dividend?

Not currently.

Is bioAffinity Technologies a good stock to buy?

We do not give buy or sell advice. bioAffinity Technologies scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.